title: NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.
abstract: The outcome of patients with metastatic renal cell carcinoma has been substantially improved with administration of the currently available molecularly targeted therapies. However, proper selection of therapy and management of toxicities remain challenging. NCCN convened a multidisciplinary task force panel to address the clinical issues associated with these therapies in attempt to help practicing oncologists optimize patient outcomes. This report summarizes the background data presented at the task force meeting and the ensuing discussion.
authors.forename: Gary R
authors.initials: GR
authors.lastname: Hudes
authors.forename: Michael A
authors.initials: MA
authors.lastname: Carducci
authors.forename: Toni K
authors.initials: TK
authors.lastname: Choueiri
authors.forename: Peg
authors.initials: P
authors.lastname: Esper
authors.forename: Eric
authors.initials: E
authors.lastname: Jonasch
authors.forename: Rashmi
authors.initials: R
authors.lastname: Kumar
authors.forename: Kim A
authors.initials: KA
authors.lastname: Margolin
authors.forename: M Dror
authors.initials: MD
authors.lastname: Michaelson
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Motzer
authors.forename: Roberto
authors.initials: R
authors.lastname: Pili
authors.forename: Susan
authors.initials: S
authors.lastname: Roethke
authors.forename: Sandy
authors.initials: S
authors.lastname: Srinivas
mesh_terms: D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome